Literature DB >> 17495229

Effect of cell-based intercellular delivery of transcription factor GATA4 on ischemic cardiomyopathy.

Jing Bian1, Zoran B Popovic, Carlos Benejam, Matthew Kiedrowski, L Leonardo Rodriguez, Marc S Penn.   

Abstract

Recent loss-of-function studies highlight the importance of the transcription factor GATA4 in the myocardial response to injury in the adult heart. However, the potential effects of gain-in-function of GATA4 overexpression, and transcription factors in general, is hindered by the fact that transcription factors are neither secreted nor taken up by cells. Chimeric proteins incorporating motifs of cell-penetrating proteins are secreted from cells and internalized by surrounding cells. We engineered a chimeric protein consisting of GATA4 and the cell-penetrating protein VP22. Cardiac fibroblasts stably transfected with the GATA4:VP22, GFP:VP22, or green fluorescent protein (GFP) constructs were transplanted into Lewis rats 1 month after left anterior descending ligation. GATA4:VP22 expression in the border zone was associated with increased cardiac myosin expression and cardiac myocyte size (30 mum versus 19 mum, P<0.01). Compared with the GFP:VP22 control group, 6 weeks after cardiac fibroblast transplantation (10 weeks after myocardial infarction), animals that received GATA4:VP22-expressing cardiac fibroblasts demonstrated increased cardiac function and less negative remodeling. These data demonstrate a novel strategy for transcription factor delivery to injured myocardium and indicate that the delivery of GATA4 locally to the infarct border zone induces multiple local effects in the border zone cardiac myocytes resulting in beneficial ventricular remodeling and improved global left ventricular function.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17495229     DOI: 10.1161/01.RES.0000269778.75877.68

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  17 in total

1.  Cardiac reprogramming factor Gata4 reduces postinfarct cardiac fibrosis through direct repression of the profibrotic mediator snail.

Authors:  Megumi Mathison; Vivek P Singh; Deepthi Sanagasetti; Lina Yang; Jaya Pratap Pinnamaneni; Jianchang Yang; Todd K Rosengart
Journal:  J Thorac Cardiovasc Surg       Date:  2017-06-21       Impact factor: 5.209

Review 2.  Genetic enhancement of stem cell engraftment, survival, and efficacy.

Authors:  Marc S Penn; Abeel A Mangi
Journal:  Circ Res       Date:  2008-06-20       Impact factor: 17.367

Review 3.  Myocardial gene transfer: routes and devices for regulation of transgene expression by modulation of cellular permeability.

Authors:  Michael G Katz; Anthony S Fargnoli; Charles R Bridges
Journal:  Hum Gene Ther       Date:  2013-04-01       Impact factor: 5.695

Review 4.  Apoptosis and acute kidney injury.

Authors:  Andrea Havasi; Steven C Borkan
Journal:  Kidney Int       Date:  2011-05-11       Impact factor: 10.612

Review 5.  Modular nanotransporters for targeted intracellular delivery of drugs: folate receptors as potential targets.

Authors:  Tatiana A Slastnikova; Andrey A Rosenkranz; Michael R Zalutsky; Alexander S Sobolev
Journal:  Curr Pharm Des       Date:  2015       Impact factor: 3.116

Review 6.  Empowering adult stem cells for myocardial regeneration.

Authors:  Sadia Mohsin; Sailay Siddiqi; Brett Collins; Mark A Sussman
Journal:  Circ Res       Date:  2011-12-09       Impact factor: 17.367

Review 7.  Pre-transplantation specification of stem cells to cardiac lineage for regeneration of cardiac tissue.

Authors:  Maritza Mayorga; Amanda Finan; Marc Penn
Journal:  Stem Cell Rev Rep       Date:  2009-01-30       Impact factor: 5.739

8.  Bone marrow support of the heart in pressure overload is lost with aging.

Authors:  Nikolai A Sopko; Benjamin A Turturice; Mitchell E Becker; Chase R Brown; Feng Dong; Zoran B Popović; Marc S Penn
Journal:  PLoS One       Date:  2010-12-21       Impact factor: 3.240

9.  Excision of HIV-1 proviral DNA by recombinant cell permeable tre-recombinase.

Authors:  Lakshmikanth Mariyanna; Poornima Priyadarshini; Helga Hofmann-Sieber; Marcel Krepstakies; Nicole Walz; Adam Grundhoff; Frank Buchholz; Eberhard Hildt; Joachim Hauber
Journal:  PLoS One       Date:  2012-02-13       Impact factor: 3.240

10.  Changes in ventricular remodelling and clinical status during the year following a single administration of stromal cell-derived factor-1 non-viral gene therapy in chronic ischaemic heart failure patients: the STOP-HF randomized Phase II trial.

Authors:  Eugene S Chung; Leslie Miller; Amit N Patel; Russell David Anderson; Farrell O Mendelsohn; Jay Traverse; Kevin H Silver; Julia Shin; Gregory Ewald; Mary Jane Farr; Saif Anwaruddin; Francis Plat; Scott J Fisher; Alexander T AuWerter; Joseph M Pastore; Rahul Aras; Marc S Penn
Journal:  Eur Heart J       Date:  2015-06-07       Impact factor: 29.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.